A Bayesian network meta-analysis of 14 molecules inhibiting UV daylight-induced pigmentation
- PMID: 38433524
- DOI: 10.1111/jdv.19910
A Bayesian network meta-analysis of 14 molecules inhibiting UV daylight-induced pigmentation
Abstract
Introduction: Hyperpigmentation disorders are very frequent, affect the quality of life and may become a psychological burden for afflicted patients. Many anti-pigmenting or depigmenting agents are available with various efficacy and almost no comparative data. 2-mercaptonicotinoyl glycine (2-MNG) was recently proposed as a viable candidate showing safe and effective results on hyperpigmentation control in vitro and in vivo.
Objectives: A Bayesian network meta-analysis (BNMA) was conducted to map and rank the anti-pigmenting and depigmenting efficacy of 2-MNG 0.5% on UV daylight (UVDL)-induced pigmentation together with 13 other reference molecules. A comparison in the kinetics of 2-MNG 0.5% was also performed.
Methodology: Fourteen studies were conducted, for each, on 15-30 women of skin phototype III in Shanghai, China and Paris, France. The products were applied on mini zone, in randomized and blinded protocol, on the back, 5 days a week during 6 weeks, at a dose of 4 mg/cm2. During the second week, volunteers were exposed under to varying minimum erythemal dose of UVDL during 4 consecutive days-adapted to obtain a similar induction of skin pigmentation regardless of the population. Assessments were performed instrumentally using Chromameter®. Ascorbic acid 7% was used as a positive control for all experiments. A Bayesian network meta-analysis was then established to map and follow the kinetics of 2-MNG 0.5% performance with 13 reference molecules (glutathione 2%, kojic acid 1%, hydroquinone 4%, ascorbyl glucoside 2%, niacinamide 4%, etc.).
Results: 2-MNG 0.5% dominated the ranking at all time points with a significant high probability of strong efficacy against UVDL-induced pigmentation. Ascorbic acid 7% ranks second after 4 days of irradiations (D12) whereas hydroquinone 4% ranks second 1 month after irradiations (D40). In the kinetics, 2-MNG at 0.5% was effective as from the end of irradiations (D12) to the study endpoint (D40). This suggested an immediate and persistent efficacy across all timepoints evaluated.
Conclusion: The BNMA revealed a rapid and lasting efficacy of 2-MNG 0.5% on the anti-pigmenting and depigmenting phases of the clinical protocol. 2-MNG 0.5% ranked first, with immediate and lasting effect compared to 13 other references. This study is the first allowing comparison between reference anti-pigmenting and depigmenting agents and will help clinicians for proposing the most effective approach for their patients.
© 2024 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Similar articles
-
Efficacy of a 2-MNG-Containing Depigmenting Serum in the Treatment of Post-Inflammatory Hyperpigmentation.J Cosmet Dermatol. 2025 Feb;24(2):e16735. doi: 10.1111/jocd.16735. Epub 2024 Dec 26. J Cosmet Dermatol. 2025. PMID: 39724317 Free PMC article.
-
2-Mercaptonicotinoyl glycine prevents UV-induced skin darkening and delayed tanning in healthy subjects: A randomized controlled clinical study.J Cosmet Dermatol. 2024 May;23(5):1745-1752. doi: 10.1111/jocd.16200. Epub 2024 Feb 19. J Cosmet Dermatol. 2024. PMID: 38372022 Clinical Trial.
-
Efficacy and safety of topical depigmenting agent in healthy human fair skin female volunteers: A single-arm study.J Cosmet Dermatol. 2018 Oct;17(5):830-839. doi: 10.1111/jocd.12435. Epub 2017 Nov 28. J Cosmet Dermatol. 2018. PMID: 29193788
-
Guide to tinted sunscreens in skin of color.Int J Dermatol. 2024 Mar;63(3):272-276. doi: 10.1111/ijd.16954. Epub 2023 Dec 10. Int J Dermatol. 2024. PMID: 38073075 Review.
-
Discovery of new depigmenting compounds and their efficacy to treat hyperpigmentation: Evidence from in vitro study.J Cosmet Dermatol. 2019 Jun;18(3):703-727. doi: 10.1111/jocd.12900. Epub 2019 Mar 13. J Cosmet Dermatol. 2019. PMID: 30866156 Review.
Cited by
-
Efficacy and Tolerability of a New Facial 2-Mercaptonicotinoyl Glycine-Containing Depigmenting Serum Versus Hydroquinone 4% over 3-Month Treatment of Facial Melasma.Dermatol Ther (Heidelb). 2025 Sep;15(9):2379-2390. doi: 10.1007/s13555-025-01473-4. Epub 2025 Jun 30. Dermatol Ther (Heidelb). 2025. PMID: 40586974 Free PMC article.
-
Efficacy of a 2-MNG-Containing Depigmenting Serum in the Treatment of Post-Inflammatory Hyperpigmentation.J Cosmet Dermatol. 2025 Feb;24(2):e16735. doi: 10.1111/jocd.16735. Epub 2024 Dec 26. J Cosmet Dermatol. 2025. PMID: 39724317 Free PMC article.
References
REFERENCES
-
- Nautiyal A, Wairkar S. Management of hyperpigmentation: current treatments and emerging therapies. Pigment Cell Melanoma Res. 2021;34(6):1000–1014.
-
- Syder NC, Quarshie C, Elbuluk N. Disorders of facial hyperpigmentation. Dermatol Clin. 2023;41:393–405.
-
- Perez‐Bernal A, Munoz‐Perez MA, Camacho F. Management of facial hyperpigmentation. Am J Clin Dermatol. 2000;1:261–268.
-
- Flament F, Mercurio DG, Catalan E, Bouhadanna E, Delaunay C, Miranda DF, et al. Impact on facial skin aging signs of a one‐year standardized photo‐protection over a classical skin care routine in skin phototypes II to VI individuals: a prospective randomized trial. J Eur Acad Dermatol Venereol. 2023;37:2090–2097. https://doi.org/10.1111/jdv.19230
-
- Wang RF, Ko D, Friedman BJ, Lim HW, Mohammad TF. Disorders of hyperpigmentation. Part I. Pathogenesis and clinical features of common pigmentary disorders. J Am Acad Dermatol. 2023;88(2):271–288.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials